Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Current Assets history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Current Assets rose 2.43% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 2.43% YoY), while the FY2025 annual figure was $1.0 billion, down 23.78% from the prior year.
• Current Assets for Q1 2026 stood at $1.3 billion, up from $1.0 billion in the prior quarter.
• The five-year high for Current Assets was $1.4 billion in Q4 2024, with the low at $284.8 million in Q2 2023.
• The 5-year median for Current Assets is $874.8 million (2024), against an average of $779.6 million.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 31.58% in 2023, then soared 207.14% in 2024.
• Crinetics Pharmaceuticals' Current Assets stood at $345.2 million in 2022, then surged by 66.33% to $574.2 million in 2023, then surged by 139.55% to $1.4 billion in 2024, then dropped by 23.78% to $1.0 billion in 2025, then grew by 26.14% to $1.3 billion in 2026.
• Business Quant data shows CRNX's Current Assets at $1.3 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.1 billion in Q3 2025.